Lineage Total Current Liabilities from 2010 to 2024
| LCTX Stock | USD 0.57 0.04 6.56% |
Total Current Liabilities | First Reported 1992-03-31 | Previous Quarter 15.3 M | Current Value 13.9 M | Quarterly Volatility 6.8 M |
Check Lineage Cell financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lineage Cell's main balance sheet or income statement drivers, such as Depreciation And Amortization of 922.5 K, Interest Expense of 6 M or Total Revenue of 9.4 M, as well as many indicators such as Price To Sales Ratio of 19.99, Dividend Yield of 0.0015 or PTB Ratio of 3.12. Lineage financial statements analysis is a perfect complement when working with Lineage Cell Valuation or Volatility modules.
Lineage | Total Current Liabilities |
Latest Lineage Cell's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Lineage Cell Therapeutics over the last few years. Total Current Liabilities is an item on Lineage Cell balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lineage Cell Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Lineage Cell's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lineage Cell's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Lineage Total Current Liabilities Regression Statistics
| Arithmetic Mean | 11,600,377 | |
| Geometric Mean | 7,395,425 | |
| Coefficient Of Variation | 97.70 | |
| Mean Deviation | 7,650,015 | |
| Median | 7,129,267 | |
| Standard Deviation | 11,333,224 | |
| Sample Variance | 128.4T | |
| Range | 46.9M | |
| R-Value | 0.62 | |
| Mean Square Error | 84.9T | |
| R-Squared | 0.39 | |
| Significance | 0.01 | |
| Slope | 1,575,052 | |
| Total Sum of Squares | 1798.2T |
Lineage Total Current Liabilities History
About Lineage Cell Financial Statements
Lineage Cell investors use historical fundamental indicators, such as Lineage Cell's Total Current Liabilities, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lineage Cell. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 18 M | 18.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.